

Company	Compound	Phase	Indication & Inclusion Criteria	Locations	Clinical Trial
Exon Skipping					
Wave Life Sciences	WVE-N531	Phase I & II	Duchenne Muscular Dystrophy 5 Years to 18 Years Amenable to skipping Exon 53	CAN, GBR	NCT04906460
Dyne Therapeutics	DYNE-251	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 16 Years Amenable to skipping Exon 51	USA (CA, CO, GA, MA, OH, UT, VA) BEL, CAN, ESP, GBR	NCT05524883 (DELIVER)
Avidity Biosciences	AOC 1044	Phase I & II	Duchenne Muscular Dystrophy 7 Years to 27 Years Amenable to skipping Exon 44	USA (CA, GA, MA, OH, TX)	NCT05670730 (EXPLORE44)
PepGen	CONNECT1-EDO51	Phase II	Duchenne Muscular Dystrophy 8 Years and up Amenable to skipping Exon 51	CAN	NCT06079736 (CONNECT1-EDO51)
NS Pharma Nippon Shinyaku	NS-089/ NCNP-02	Phase II	Duchenne Muscular Dystrophy 4 Years to 14 years Ambulatory Amenable to exon 44 skipping	USA (CO, GA, IL, KS, OH, OR, PA, TX, VA)	NCT05996003
NS Pharma Nippon Shinyaku	NS-050/ NCNP-03	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 14 years Ambulatory Amenable to exon 50 skipping	TBD	NCT06053814 (Meteor50)
Gene Therapy					
Sarepta Therapeutics	SRP-9001 (Delandistrogene Moxeparvovec)	Phase III	Duchenne Muscular Dystrophy Non-ambulatory or Ambulatory 8 Years to 18 Years	USA (AR, CA, FL, IL, IA, MO, NY, NC, PA, VA)	NCT05881408 (ENVISION)
RegenexBio	RGX-202	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 11 Years Ambulatory Mutation in Exons 18 and above	USA (CA, AR, IL)	NCT05693142 (AFFINITY DUCHENNE)
Roche	Delandistrogene Moxeparvovec	Phase II	Duchenne Muscular Dystrophy Up to 4 Years Mutation between Exons 18 and 79	ESP	NCT06128564 (ENVOL)

Solid Biosciences	SGT-003	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 8 Years Ambulatory	USA (CA, OH)	NCT06138639 (INSPIRE DUCHENNE)
Muscle Stabilizer					
Edgewise Therapeutics	EDG-5506	Phase II	Duchenne Muscular Dystrophy 4 Years to 9 Years Ambulatory	USA (AR, CA, CO, FL, GA, IA, KS, MA, MD, MO, OH, TX)	NCT05540860 (LYNX)
Edgewise Therapeutics	EDG-5506	Phase II	Becker Muscular Dystrophy 12 Years to 50 Years Ambulatory	USA (AR, CA, CO, IA, KS, MD, MA, MO, OH, VA) NED, GBR	NCT05291091 (GRAND CANYON)
Edgewise Therapeutics	EDG-5506	Phase II	Duchenne Muscular Dystrophy 6 Years to 14 Years Ambulatory Previous treated with an AAV-based gene therapy	USA (CA, FL, MA, MO, NC, OH)	NCT06100887 (FOX)
Cell Therapy					
Capricor	CAP-1002	Phase III	Duchenne Muscular Dystrophy 10 Years and older	USA (AR, AZ, CA, CO, GA, IA, IL, MA, MI, OH, TX, UT, VA, WA, WI)	NCT05126758 (HOPE-3)
Anti-inflammatory					
Taiho Pharmaceutical	TAS-205	Phase III	Duchenne Muscular Dystrophy 5 Years and older Ambulatory	JPN	NCT04587908 (REACH-DMD)
ReveraGen BioPharma	Vamorolone	Phase II	Duchenne Muscular Dystrophy 2 Years to 17 Years	CAN	NCT05185622
ReveraGen BioPharma	Vamorolone	Phase II	Becker Muscular Dystrophy 18 Years to 64 Years Ambulatory	USA (PA)	NCT05166109
Nationwide Children's Hospital Children's Hospital of Chicago Children's Hospital Medical Center, Cincinnati	Prednisolone	Phase IV	Duchenne Muscular Dystrophy 1 Month to 30 Months	USA (IL, OH, TX, VA)	NCT05412394

University of Florida U.S. Army Medical Research and Development Command	Prednisone	Phase II	Duchenne Muscular Dystrophy 5 Years to 8 Years Ambulatory	USA (FL)	NCT04322357
Cardiac Function					
Medical University of Gdansk	Metoprolol Succinate	Phase III	Duchenne Muscular Dystrophy 8 Years to 17 Years	POL	NCT05066633
Peking Union Medical College Hospital	Bisoprolol Fumarate	Phase II & III	Duchenne Muscular Dystrophy 7 Years and older	CHN	NCT03779646
Cumberland Pharmaceuticals Vanderbilt University Medical Center	Ifetroban	Phase II	Duchenne Muscular Dystrophy 7 Years and older	USA (AR, CA, DC, GA, IL, IN, MD, MO, OH, TN)	NCT03340675